Literature DB >> 2442509

Felodipine in hypertension--a review.

D Elmfeldt, T Hedner, S Westerling.   

Abstract

Felodipine lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. The selective action may be considered a safeguard against untoward effects on cardiac contractility and conduction. Felodipine does not cause orthostatic hypotension since it has no effect in clinical doses on venous smooth muscle. Felodipine has a natriuretic/diuretic effect, which counteracts the salt and water retention that is often seen during treatment with other potent vasodilators. In clinical studies, felodipine has proved more effective than several established antihypertensive drugs. The combination of felodipine and a beta-adrenergic blocker appears to be a good alternative to standard triple treatment, and felodipine is often effective in patients with previously "refractory" hypertension. The antihypertensive effect of felodipine is dose related. In patients with moderate hypertension, a dose regimen of 5 mg twice a day is usually sufficient, and doses greater than 10 mg twice a day are not often required. Felodipine is generally well tolerated. The most common adverse effects are those expected from a potent arteriolar dilator: ankle swelling, headache, dizziness, flushing, etc. Adverse effects are usually transient or diminish in intensity with continued treatment. The overall frequency of adverse effects with felodipine appears to be similar to that for the established antihypertensive drugs, although the adverse effects differ. Felodipine is a potent arteriolar dilator with therapeutic advantages, especially for patients with moderate to severe hypertension.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442509

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  The haemodynamic effects of long term felodipine therapy in previously untreated essential hypertension.

Authors:  S Capewell; C G Wathen; W J Hannan; A L Muir
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Hemodynamic interactions between diuretics and calcium antagonists in the treatment of hypertensive patients.

Authors:  S Di Somma; V Liguori; M Petitto; G Cavallotti; S Savonitto; O de Divitiis
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol.

Authors:  B Bengtsson-Hasselgren; D Elmfeldt; L Moberg; O Rönn
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo.

Authors:  A Bossini; C Di Veroli; G Cavallotti; V Cagli
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

5.  Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension.

Authors:  T Hedner; D Elmfeldt; C Dahlöf; E Sjögren
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Comparison of once daily felodipine 10 mg ER and hydrochlorothiazide 25 mg in the treatment of mild to moderate hypertension.

Authors:  W Koenig; M Sund; L Binner; R Hehr; J Rosenthal; V Hombach
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.